Drugs in ATC Class B02BC

Up to Top Level ATC Classes

Up to B - Blood and blood forming organs

Up to B02 - ANTIHEMORRHAGICS

Up to B02B - VITAMIN K AND OTHER HEMOSTATICS

Drugs in ATC Class: B02BC - Local hemostatics

Tradename	Generic Name
ARTICAINE HYDROCHLORIDE AND EPINEPHRINE BITARTRATE	articaine hydrochloride; epinephrine bitartrate
BUPIVACAINE HYDROCHLORIDE AND EPINEPHRINE	bupivacaine hydrochloride; epinephrine
BUPIVACAINE HYDROCHLORIDE AND EPINEPHRINE	bupivacaine hydrochloride; epinephrine bitartrate
ORABLOC	articaine hydrochloride; epinephrine bitartrate
SEPTOCAINE	articaine hydrochloride; epinephrine bitartrate
ULTACAN	articaine hydrochloride; epinephrine bitartrate
ULTACAN FORTE	articaine hydrochloride; epinephrine bitartrate

B02BC Market Analysis and Financial Projection

The market for ATC Class B02BC local hemostatics is expanding due to increasing surgical volumes, technological advancements, and demand for biocompatible solutions. Here’s a detailed analysis:

Market Dynamics

• Growth Drivers:

  • The global topical hemostat market is projected to grow at a 6.85% CAGR, reaching USD 3.36 billion by 2030, driven by rising surgical procedures (orthopedic, cardiovascular, neurological) and chronic disease prevalence[3][6][12].
  • Oxidized regenerated cellulose (ORC) dominates product segments (e.g., B02BC02) due to biocompatibility and rapid clotting, holding ~30% market share[6][12].
  • North America leads regionally (40% market share) owing to advanced healthcare infrastructure and high adoption rates, while Asia-Pacific shows fastest growth due to expanding medical access and surgical demand[6][12].

• Innovation Trends:

  • Development focuses on combination hemostats (B02BC30) and materials like collagen (B02BC07) or calcium alginate (B02BC08) that enhance clotting and tissue repair[1][6].
  • Minimally invasive surgeries boost demand for flowable and sprayable formulations, reducing procedural complexity[12][16].

• Challenges:

  • High costs of thrombin-based products (B02BC06) and skill gaps in applying advanced hemostats limit adoption in emerging markets[6][12].
  • Regulatory hurdles and reimbursement variability (e.g., Europe vs. Asia-Pacific) slow market entry for novel agents[3][5].

Patent Landscape

• Key Innovations:

  • US4215106A: A polyacrylic acid-based hemostat achieving coagulation in 1–2 seconds, effective in impaired coagulation systems[4].
  • US9364578B2: Chitosan-fiber matrices for internal bleeding control, enhancing wound sealing and reducing re-bleeding risks[15].
  • US8912168B2: Modified starch materials that bond tissues and prevent adhesions, offering cost-effective alternatives to traditional agents[11].

• Strategic Trends:

  • Over 45% of recent patents focus on biodegradable materials (e.g., gelatin, collagen) and hybrid systems combining mechanical barriers with clotting activators (e.g., thrombin + cellulose)[8][15].
  • Patent filings highlight regional R&D disparities, with North America and Europe accounting for 70% of IP activity, while Asia-Pacific focuses on generics[8][16].

Regional Opportunities

• Asia-Pacific: Rising investments in healthcare infrastructure and a 12% annual increase in surgical volumes create demand for affordable hemostats like gelatin sponges (B02BC01)[3][12].
• Europe: Stricter regulations drive innovation in ORC and collagen-based products, with combinations (B02BC30) gaining traction in trauma care[6][9].

Future Outlook

Emerging gene therapy-derived hemostats and AI-driven product formulations aim to address clotting disorders and personalize treatment. Meanwhile, cost pressures will favor biosimilars and starch/chitosan-based agents in price-sensitive markets[11][15][16].

"The interaction of the proposed hemostatic with native blood [...] took 1–2 seconds to produce a firm clot of proteins." – US4215106A[4].

This synthesis underscores a sector poised for growth through material innovation and geographic expansion, albeit constrained by skill and cost barriers.

References

1. https://www.atccode.com/B02BC
2. https://www.chicot-ph.com/images/book/journal/rem/131-134-PB.pdf
3. https://www.360iresearch.com/library/intelligence/topical-hemostat
4. https://patents.google.com/patent/US4215106A/en
5. https://pure.hud.ac.uk/files/67009246/28_Final_thesis.pdf
6. https://www.marketsandmarkets.com/Market-Reports/hemostats-market-9571619.html
7. https://www.globenewswire.com/news-release/2024/02/14/2828930/0/en/Hemostat-Market-Size-to-Surpass-USD-5-7-Billion-by-2033-Rising-prevalence-of-chronic-diseases-and-increasing-surgical-procedures.html
8. https://www.expertmarketresearch.com/patent-analysis/hemostats-patent-landscape
9. https://atcddd.fhi.no/atc_ddd_index/?code=B02BC&showdescription=yes
10. https://atcddd.fhi.no/atc_ddd_index/?code=B02B
11. https://patents.google.com/patent/US8912168B2/en
12. https://www.databridgemarketresearch.com/reports/global-hemostats-market
13. https://prediction.charite.de/subpages/tree.php
14. https://www.aifa.gov.it/documents/20142/2594020/AIFA_Rapporto_OsMed_2023_EN.pdf
15. https://patents.google.com/patent/US9364578B2/en
16. https://www.biospace.com/hemostats-market-major-trends-drivers-key-players-and-regional-assessment